232,597 Shares in Lantheus Holdings, Inc. $LNTH Acquired by William Blair Investment Management LLC

William Blair Investment Management LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to its most recent filing with the SEC. The fund acquired 232,597 shares of the medical equipment provider’s stock, valued at approximately $25,804,000. William Blair Investment Management LLC owned approximately 0.36% of Lantheus at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Heron Bay Capital Management purchased a new stake in shares of Lantheus during the second quarter worth $4,367,000. Keating Financial Advisory Services Inc. purchased a new position in shares of Lantheus in the second quarter valued at $404,000. Allworth Financial LP bought a new stake in shares of Lantheus during the 2nd quarter valued at $49,000. Vise Technologies Inc. bought a new stake in shares of Lantheus during the 2nd quarter valued at $503,000. Finally, Great Lakes Advisors LLC purchased a new stake in Lantheus during the 2nd quarter worth about $4,069,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $99.97 on Friday. The company’s fifty day moving average price is $104.08 and its 200-day moving average price is $90.35. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The firm has a market capitalization of $6.53 billion, a price-to-earnings ratio of 24.15 and a beta of -0.03. Lantheus Holdings, Inc. has a one year low of $49.67 and a one year high of $111.86.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same period in the previous year, the firm posted $1.57 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Mizuho lowered their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 29th. Leerink Partners set a $102.50 price target on shares of Lantheus in a research report on Monday, August 3rd. B. Riley Financial lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Citizens Jmp restated a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Hold” and an average target price of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.